Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 23;12(12):1311.
doi: 10.3390/vaccines12121311.

Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains

Ana C B Terzian  1 , Sasha R Azar  2   3 , Cassia F Estofolete  4   5 , Mauricio L Nogueira  4   5 , Nikos Vasilakis  3   6   7
Affiliations

Differential Neutralization Profiles of 17DD Vaccinated Population to 17D-204 and 17DD Vaccine Strains

Ana C B Terzian et al. Vaccines (Basel). .

Abstract

Background/Objectives: Yellow fever virus (YFV) (Flaviviridae, Orthoflavivirus) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. Methods: The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. Results: Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT50 183, PRNT80 86, median reciprocal PRNT50 80, and PRNT80 40) compared to 17D-204 (mean reciprocal PRNT50 91, PRNT80 33, median reciprocal PRNT50 40, and PRNT80 10). Conclusions: Our data indicate antigenic differences between 17D and 17DD vaccines.

Keywords: YFV; immune response; neutralizing antibodies; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Reciprocal Plaque Reduction Neutralization Test (PRNT) titers of the study population. Reciprocal neutralization titers of the 209 serum samples against either YFV 17D-204 or 17DD. (A) Representation of 50% neutralization titer against designated vaccine strain. (B) Representation of 50% neutralization titer against designated vaccine strain. Bold lines within the boxes represent median values. Between-group comparisons were made using the nonparametric Mann–Whitney test to detect differences in median values. **** p < 0.0001.
See this image and copyright information in PMC

References

    1. ICTV . Virus Taxonomy: 2023 Release (MSL #39) ICTV; Jena, Germany: 2023. [(accessed on 24 September 2024)]. Available online: https://ictv.global/taxonomy.
    1. Pierson T.C., Diamond M.S. Flaviviruses. In: Knipe D.M., Howley P.M., editors. Fields Virology. 6th ed. Volume 1. Wolters Kluwer Health Adis (ESP); Philadelphia, PA, USA: 2013. p. 2664.
    1. Fischer C., de Oliveira-Filho E.F., Drexler J.F. Viral emergence and immune interplay in flavivirus vaccines. Lancet Infect. Dis. 2020;20:15–17. doi: 10.1016/S1473-3099(19)30697-8. - DOI - PubMed
    1. Ishikawa T., Yamanaka A., Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014;32:1326–1337. doi: 10.1016/j.vaccine.2014.01.040. - DOI - PubMed
    1. Dutta S.K., Langenburg T. A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses. 2023;15:860. doi: 10.3390/v15040860. - DOI - PMC - PubMed

LinkOut - more resources